<DOC>
	<DOCNO>NCT00190762</DOCNO>
	<brief_summary>Based result earlier clinical trial , Pemetrexed may antitumor activity first-line agent treatment mesothelioma . Given , hypothesize Pemetrexed may active second-line mesothelioma standard treatment best supportive care . This study compare survival previously treat patient malignant pleural mesothelioma receive Pemetrexed plus best supportive care survival similar patient receive best supportive care alone .</brief_summary>
	<brief_title>A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone Treatment Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically proven diagnosis mesothelioma pleura . receive one prior systemic chemotherapy regimen advance metastatic disease Performance status 70 high Karnofsky Performance Status Scale Males females least 18 year age Adequate organ function Active infection opinion investigator would compromise patient 's ability tolerate therapy Pregnancy breastfeed Brain metastasis Prior treatment Pemetrexed Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>